Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | ADK | P55263 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.49 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707731 | 1.00 | NPC1 (0.64) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL29419010 | 0.89 | KMT2A (0.80) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL28595722 | 0.89 | KMT2A (0.80) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL709611 | 0.89 | MEN1 (0.54) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL709612 | 0.89 | MEN1 (0.54) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL8787427 | 0.83 | NPC1 (0.52) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL30195162 | 0.83 | MEN1 (0.76) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL29389283 | 0.83 | MEN1 (0.76) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL461985 | 0.83 | MEN1 (0.76) | NPC1RAB9AMEN1KMT2AATM | |
| SCHEMBL461986 | 0.83 | MEN1 (0.76) | NPC1RAB9AMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116851-B1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INST FOR BIOLOGICAL STUDI (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-116120224-A | Synthesis method of chiral beta-aza-arene tertiary carbon center compound | 河南工业大学 | 2023-05-16 | — | — | CN | disclosed |
| US-20210147365-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-05-20 | — | — | US | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | NPC1 19/4885RAB9A 4723/4885MEN1 3997/4885 |
| US-20210147365-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | NPC1 1094/4885RAB9A 1899/4885MEN1 2454/4885 |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | NPC1 1094/4885RAB9A 1899/4885MEN1 2454/4885 |
| US-20070276011-A1 | Plasminogen Activator Inhibitor-1 Inhibitor | SERPINE1, SERPINC1, SERPINB1 | NPC1 3368/4885RAB9A 3765/4885MEN1 2892/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | NPC1 48/4885RAB9A 4606/4885MEN1 3163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.